Literature DB >> 1568472

Ganglio-N-tetraosylceramide (GA1) of bovine and human brain. Molecular characterization and presence in myelin.

S Dasgupta1, H van Halbeek, E L Hogan.   

Abstract

During our studies of bovine brain neutral glycosphingolipids (Ngsl's), we have purified a compound that co-migrates on thin-layer chromatogram with standard GA1 (purified by acid hydrolysis of GM1) and close to penta- (nLc5Cer) glycosylceramide from bovien erythrocytes. The structure of the purified Ngsl from brain has been established by permethylation and by stepwise exoglycosidase hydrolysis. 600 MHz 1H NMR spectroscopy of the oligosaccharide obtained from the Ngsl after endoglycoceramidase hydrolysis confirms the structure as ganglio-N-tetraosylceramide (GgOse4Cer or GA1) as Gal beta 1----3GalNAc beta 1----4Gal beta 1----4Glc beta 1----1Cer. We have identified GA1 in bovine, rat and human brain and myelin by TLC-immunostaining with monospecific anti-GA1 antiserum.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1568472     DOI: 10.1016/0014-5793(92)81234-d

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

1.  Stage-specific expression of fuco-neolacto- (Lewis X) and ganglio-series neutral glycosphingolipids during brain development: characterization of Lewis X and related glycosphingolipids in bovine, human and rat brain.

Authors:  S Dasgupta; E L Hogan; S S Spicer
Journal:  Glycoconj J       Date:  1996-06       Impact factor: 2.916

2.  Infectious Entry and Neutralization of Pathogenic JC Polyomaviruses.

Authors:  Eileen M Geoghegan; Diana V Pastrana; Rachel M Schowalter; Upasana Ray; Wei Gao; Mitchell Ho; Gary T Pauly; Dina M Sigano; Campbell Kaynor; Ellen Cahir-McFarland; Benoit Combaluzier; Jan Grimm; Christopher B Buck
Journal:  Cell Rep       Date:  2017-10-31       Impact factor: 9.423

3.  AsialoGM1 and integrin alpha2beta1 mediate prostate cancer progression.

Authors:  Severine Van Slambrouck; John Hilkens; Marco Bisoffi; Wim F A Steelant
Journal:  Int J Oncol       Date:  2009-10       Impact factor: 5.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.